LUMINITY

This brand name is authorized in Austria, Croatia, Estonia, Ireland, Italy, Lithuania, Poland, Romania, Spain, UK.

Active ingredients

The drug LUMINITY contains one active pharmaceutical ingredient (API):

1	Perflutren UNII CK0N3WH0SR - PERFLUTREN
	When used in conjunction with diagnostic ultrasound, perflutren provides opacification of cardiac chambers, improvement in delineation of endocardial borders, enhancement of the Doppler signal, and visualisation of wall motion and blood flow within the heart.
	Read more about Perflutren

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LUMINITY Gas and solvent for dispersion for injection/infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V08DA04		V Various → V08 Contrast media → V08D Ultrasound contrast media → V08DA Ultrasound contrast media
Discover more medicines within V08DA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1266869, 1537905
ES	Centro de información online de medicamentos de la AEMPS	06361001
GB	Medicines & Healthcare Products Regulatory Agency	135637
IT	Agenzia del Farmaco	037379017, 037379029
LT	Valstybinė vaistų kontrolės tarnyba	1029638, 1029639
PL	Rejestru Produktów Leczniczych	100311659
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W54777001, W54777002